<DOC>
	<DOCNO>NCT00906828</DOCNO>
	<brief_summary>The purpose study determine whether oral intake COMT inhibitor affect smooth plasma levodopa level achieve intestinal levodopa/carbidopa infusion advance Parkinson 's disease patient . The hypothesis COMT inhibitor make plasma concentration levodopa fluctuating .</brief_summary>
	<brief_title>Pharmacokinetics Levodopa/Carbidopa Infusion With Without Oral Catechol-O-methyl Transferase ( COMT ) Inhibitors</brief_title>
	<detailed_description>The aim measure variability plasma levodopa level follow three treatment : Day 1 : Duodopa individually optimise dose Day 2 : 80 % optimised Duodopa dose + two tablet entacapone t=0 hour t= 6 hour Day 3 : 80 % optimised Duodopa dose + two tablet tolcapone t=0 hour t= 6 hour Plasma sample determination levodopa concentration take every 30 minute 8 hour . Video recording perform every 30 min 8 hour , later blind assessment 2-3 expert . Sequences randomise order . Patient self-scores regard mobility record , every 30 min 8 hour .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Tolcapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Catechol O-Methyltransferase Inhibitors</mesh_term>
	<criteria>Parkinson 's disease Duodopa treatment ongoing Hoehn &amp; Yahr stage 35 bad Ongoing treatment COMT inhibitor Dementia Psychosis Treatment typical neuroleptic Contraindications entacapone tolcapone</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Levodopa/carbidopa infusion</keyword>
	<keyword>entacapone</keyword>
	<keyword>tolcapone</keyword>
	<keyword>efficacy</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>